These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 18775614)

  • 41. Prospective comparison of Fibroscan, King's score and liver biopsy for the assessment of cirrhosis in chronic hepatitis C infection.
    Cross TJ; Calvaruso V; Maimone S; Carey I; Chang TP; Pleguezuelo M; Manousou P; Quaglia A; Grillo F; Dhillon AP; Dusheiko GM; Burroughs AK; Harrison PM
    J Viral Hepat; 2010 Aug; 17(8):546-54. PubMed ID: 19874477
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Usefulness of non-invasive markers for predicting liver cirrhosis in patients with chronic hepatitis B.
    Lee KG; Seo YS; An H; Um SH; Jung ES; Keum B; Yim HJ; Jeen YT; Chun HJ; Kim CD; Ryu HS
    J Gastroenterol Hepatol; 2010 Jan; 25(1):94-100. PubMed ID: 19793171
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Assessment of FIBROSpect II to detect hepatic fibrosis in chronic hepatitis C patients.
    Zaman A; Rosen HR; Ingram K; Corless CL; Oh E; Smith K
    Am J Med; 2007 Mar; 120(3):280.e9-14. PubMed ID: 17349453
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease.
    Naveau S; Gaudé G; Asnacios A; Agostini H; Abella A; Barri-Ova N; Dauvois B; Prévot S; Ngo Y; Munteanu M; Balian A; Njiké-Nakseu M; Perlemuter G; Poynard T
    Hepatology; 2009 Jan; 49(1):97-105. PubMed ID: 19053048
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Non-invasive biomarkers FibroTest-ActiTest for replacing invasive liver biopsy: the need for change and action.
    Munteanu M
    J Gastrointestin Liver Dis; 2007 Jun; 16(2):173-4. PubMed ID: 17592566
    [No Abstract]   [Full Text] [Related]  

  • 46. Early detection in routine clinical practice of cirrhosis and oesophageal varices in chronic hepatitis C: comparison of transient elastography (FibroScan) with standard laboratory tests and non-invasive scores.
    Castéra L; Le Bail B; Roudot-Thoraval F; Bernard PH; Foucher J; Merrouche W; Couzigou P; de Lédinghen V
    J Hepatol; 2009 Jan; 50(1):59-68. PubMed ID: 19013661
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Non-invasive biomarkers of liver fibrosis in haemophilia patients with hepatitis C: can you avoid liver biopsy?
    Maor Y; Bashari D; Kenet G; Lubetsky A; Luboshitz J; Schapiro JM; Pénaranda G; Bar-Meir S; Martinowitz U; Halfon P
    Haemophilia; 2006 Jul; 12(4):372-9. PubMed ID: 16834736
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The APRI may be enhanced by the use of the FIBROSpect II in the estimation of fibrosis in chronic hepatitis C.
    Snyder N; Nguyen A; Gajula L; Soloway R; Xiao SY; Lau DT; Petersen J
    Clin Chim Acta; 2007 Jun; 381(2):119-23. PubMed ID: 17442291
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Diagnostic value of serum protein profiling by SELDI-TOF ProteinChip compared with a biochemical marker, FibroTest, for the diagnosis of advanced fibrosis in patients with chronic hepatitis C.
    Morra R; Munteanu M; Bedossa P; Dargere D; Janneau JL; Paradis V; Ratziu V; Charlotte F; Thibault V; Imbert-Bismut F; Poynard T
    Aliment Pharmacol Ther; 2007 Sep; 26(6):847-58. PubMed ID: 17767469
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Performance of noninvasive markers for liver fibrosis is reduced in chronic hepatitis C with normal transaminases.
    Sebastiani G; Vario A; Guido M; Alberti A
    J Viral Hepat; 2008 Mar; 15(3):212-8. PubMed ID: 18179453
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Circulating level of large splice variants of tenascin-C is a marker of piecemeal necrosis activity in patients with chronic hepatitis C.
    Tanaka H; El-Karef A; Kaito M; Kinoshita N; Fujita N; Horiike S; Watanabe S; Yoshida T; Adachi Y
    Liver Int; 2006 Apr; 26(3):311-8. PubMed ID: 16584393
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma.
    Durazo FA; Blatt LM; Corey WG; Lin JH; Han S; Saab S; Busuttil RW; Tong MJ
    J Gastroenterol Hepatol; 2008 Oct; 23(10):1541-8. PubMed ID: 18422961
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Non-invasive evaluation of liver fibrosis in hepatitis C].
    de Lédinghen V; Poynard T; Wartelle C; Rosenthal E
    Gastroenterol Clin Biol; 2008 Mar; 32(3 Pt 2):S90-5. PubMed ID: 18675186
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Altered pattern of circulating matrix metalloproteinases -2,- 9 and tissue inhibitor of metalloproteinase-2 in patients with HCV-related chronic hepatitis. Relationship to histological features.
    Bruno CM; Valenti M; Bertino G; Ardiri A; Consolo M; Mazzarino CM; Amoroso A; Neri S
    Panminerva Med; 2009 Dec; 51(4):191-6. PubMed ID: 20195229
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A multicentre study of the usefulness of liver biopsy in hepatitis C.
    Bain VG; Bonacini M; Govindarajan S; Ma M; Sherman M; Gibas A; Cotler SJ; Deschenes M; Kaita K; Jhangri GS
    J Viral Hepat; 2004 Jul; 11(4):375-82. PubMed ID: 15230861
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Biomarkers of fibrosis and impaired liver function in chronic hepatitis C: how well do they predict clinical outcomes?
    Peters L; Rockstroh JK
    Curr Opin HIV AIDS; 2010 Nov; 5(6):517-23. PubMed ID: 20978395
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C.
    Poynard T; Munteanu M; Imbert-Bismut F; Charlotte F; Thabut D; Le Calvez S; Messous D; Thibault V; Benhamou Y; Moussalli J; Ratziu V
    Clin Chem; 2004 Aug; 50(8):1344-55. PubMed ID: 15192028
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Intra-laboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donors.
    Imbert-Bismut F; Messous D; Thibault V; Myers RB; Piton A; Thabut D; Devers L; Hainque B; Mercadier A; Poynard T
    Clin Chem Lab Med; 2004 Mar; 42(3):323-33. PubMed ID: 15080567
    [TBL] [Abstract][Full Text] [Related]  

  • 59. FibroScan and FibroTest to assess liver fibrosis in HCV with normal aminotransferases.
    Castera L; Foucher J; Bertet J; Couzigou P; de Ledinghen V
    Hepatology; 2006 Feb; 43(2):373-4; author reply 375-6. PubMed ID: 16440359
    [No Abstract]   [Full Text] [Related]  

  • 60. Optimal correlation between different instruments for Fibrotest-Actitest protein measurement in patients with chronic hepatitis C.
    Rosenthal-Allieri MA; Tran A; Halfon P; Imbert-Bismut F; Munteanu M; Messous D; Peritore ML; Poynard T; Bernard A
    Gastroenterol Clin Biol; 2007 Oct; 31(10):815-21. PubMed ID: 18166859
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.